Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Afinitor Everolimus Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) Do not list Complete
Afinitor Everolimus Pancreatic Neuroendocrine Tumour Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Advanced Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Aimovig erenumab Migraine Reimburse with clinical criteria and/or conditions Complete
Ajovy fremanezumab migraine Reimburse with clinical criteria and/or conditions Complete
Akeega niraparib abiraterone acetate Metastatic castration-resistant prostate cancer (mCRPC) Reimburse with clinical criteria and/or conditions Complete
Akynzeo netupitant / palonosetron Nausea and vomiting (chemotherapy induced) prevention Reimburse with clinical criteria and/or conditions Complete
Albrioza sodium phenylbutyrate and ursodoxicoltaurine Amyotrophic lateral sclerosis (ALS) Reimburse with clinical criteria and/or conditions Complete
Aldurazyme Laronidase Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie Do not list Complete
Alecensaro Alectinib Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete